Overview

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Status:
Completed

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy. It is not yet known whether treatment with zoledronate is effective in preventing bone-related events in patients who have prostate cancer and bone metastases. PURPOSE: This randomized phase III trial is studying how well zoledronate works in preventing bone-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases.

Phase:

Phase 3

Details

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborators:

Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
NCIC Clinical Trials Group
Novartis Pharmaceuticals
Southwest Oncology Group

Treatments:

Androgens
Ascorbic Acid
Calcium
Calcium, Dietary
Deslorelin
Diphosphonates
Ergocalciferols
Estrogens, Conjugated (USP)
Methyltestosterone
Vitamin D
Vitamins
Zoledronic Acid